



NEWS RELEASE

Charleston Laboratories, Inc. Appoints Bill Kozarek Ph.D Vice President of Product Development

A Versatile, Proven and Industry Leading Executive

Charleston, South Carolina – September 3, 2012 – Charleston Laboratories, Inc, an emerging specialty pharmaceutical company focused on the research and development of novel pain products that prevent or significantly reduce nausea and vomiting related to opioid analgesics and other pain associated disease states, announced today the appointment of Bill Kozarek Ph.D, as Vice President of Product Development.

"We are thrilled to have Dr. Kozarek's experience and leadership as a part of our drug development programs" said Paul Bosse, President and Chief Executive Officer of Charleston.

"Dr. Kozarek has an uncanny ability to drive results through creative and strategic thinking and will play a pivotal role towards the innovation of our pipeline."

Dr. Kozarek has enjoyed a successful 40 year career where he has been recognized for his extensive experience in Rx and OTC drugs. He played key roles in the Rx to OTC switch of Prilosec, Aleve, and Femstat. Dr. Kozarek has participated in over 30 IND programs and 12 NDA programs including 8 original NDAs and 2 ANDAs, numerous FDA meetings and advisory panels.

Dr. Kozarek received a Ph.D. in Analytical Chemistry from the University of Arizona and has been an adjunct professor at the University of Cincinnati, School of Pharmacy.

"I am very excited to be part of the Charleston organization" said Dr. Kozarek, Vice President of Product Development of Charleston. "Charleston has exceptional talent, a truly visionary line of product concepts, and a strong focus on the patient needs. It is a honor to work with such capable colleagues. I look forward to the challenges to gain FDA approval of Charleston's first new drug product."

About Charleston Laboratories, Inc.

Charleston Laboratories, Inc is a specialty pharmaceutical company focused on the research and development of novel pain products that prevent or significantly reduce nausea and vomiting, the two most burdensome side effects related to opioid analgesics and other pain associated disease states. Charleston's new products will address Opioid Induced Nausea and Vomiting (OINV), Postoperative Nausea and Vomiting (PONV), Chemotherapy Induced Nausea and Vomiting (CINV), Radiation Induced Nausea and Vomiting (RINV), and Migraine Induced Nausea and Vomiting (MINV). In addition, Charleston is developing other products without acetaminophen to reduce the potential for liver injury and formulations with abuse deterrent technologies designed to curb misuse and abuse. Charleston Laboratories intends to enter into discovery and commercialization alliances with partners motivated to introduce novel pain therapies that eliminate or significantly reduce nausea and vomiting.

www.charlestonlabs.com.

###